PBS Biotech, a Camarillo-based startup co-founded by a former Amgen scientist, is bringing its first products to market.
PBS makes a line of what are known as disposable bioreactors, a simpler and less costly alternative to the stainless steel tanks that biotechnology companies use to grow cells and make medicines. The firm was founded after hundreds of employees were laid off at Thousand Oaks-based Amgen, the world’s largest biotechnology firm, and has been funded with a $250,000 loan from the Economic Development Collaborative-Ventura County, or EDC-VC, as well as private investor backing.
PBS is focused on bioreactors, the equipment biotechnology firms use to grow cells in a vat of liquid. A typical bioreactor is made of stainless steel and has to be painstakingly cleaned between runs of cells. The PBS version uses a disposable plastic lining that is sterilized by gamma rays during manufacturing and saves on costs, CEO Brian Lee told the Business Times.
But Lee, who holds a doctorate and who worked in bioprocess engineering at Merck & Co. for 13 years and at Amgen for five years, said the PBS bioreactor is also gentler on the cells it grows.
Where conventional bioreactors work like an old-style milkshake mixer to stir up the cell culture, the PBS version uses what looks like a reverse water wheel to keep things moving. A bubble of oxygen or other gases — which are already required to keep the cells fed — turns a submerged wheel.
“A stainless steel bioreactor is like the landline telephone system — it’s an old system that has worked for 70 years, but it’s not very flexible.” Today’s disposable bioreactors, Lee said, are akin to the brick-like mobile phones of the late 1980s and early 1990s. He said he envisions the PBS reactor as “just like the iPhone or the smart phone of bioreactors.”
Lee said another advantage of the disposable liners that they cut down time between batches of cells. “You can make more runs with a quick turnaround,” Lee said. “It’s really priceless to have that kind of flexibility.”
The U.S. Department of Defense thinks similarly. It provided a grant of about $750,000 to PBS Biotech to help the firm develop its products. Lee said the Defense Department is interested in the disposable bioreactor industry because portable versions could be used for an emergency response to bioterrorism at home and biological weapons attacks on U.S. troops abroad.
“I was invited to the Pentagon to brief the Honorable Andrew Weber,” the assistant secretary of defense for nuclear, chemical and biological defense programs, Lee said. “Even the federal government has started to pay attention to this. It’s really a matter of when, not if” the federal government embraces the industry.
For the past two years, PBS has been perfecting its line of bioreactors and the software that runs them, which it wrote from the ground up. The lineup includes units that range from a three-liter tabletop mixer aimed at labs and biotech startups to 2,500-liter machine that would stand 9 feet tall and be used for high-volume production runs. That model is due out next year.
“Eventually, what we’d like to see is reducing stainless steel even at the production stage,” Lee said. “We don’t know when the tipping point will come. No one believed when the cell phone came out that it would replace the landline — it was only for emergencies. Now less than 50 percent of American households have a landline. The time will come.”
Bruce Stenslie, the CEO of EDC-VC, said PBS’ potential for sales to different biotechnology market segments played into why EDC-VC found the young company creditworthy.
“It works for university R&D and other kinds of research labs. But it also works in the production side for the private sector,” Stenslie said. “We see a lot of folks who are developing products and services in biotechnology or medical devices who are not so well diversified.”
PBS sees a potentially large market in makers of so-called biosimilars, which are the biotech equivalent of generic drugs. Because biotech medicines usually employ huge, complicated molecules, competitors can often change a few small pieces of it and have a drug that works nearly as well as the original from a company like Amgen or Genentech.
Those competitors can also use an expedited FDA process for drug approval — but they must supply their own data, and generating those clinical trial numbers is the costliest part of the process in bringing about a drug. Amgen and other biotech firms fought hard to keep their data exclusive, but in the end the U.S. Congress settled on 12 years of data exclusivity for Amgen and other makers.
The end result is that there will be a wave of cheaper biosimilars entering the market in coming years, and PBS is hoping to sell to those companies.
After 30 years of rapidly introducing new treatments, “the biotechnology market is changing,” said Jim Schultz, the vice president of sales and development at PBS. “All of those drugs are coming out of patent. There’s global demand” for cheaper biosimilars, he said.
While PBS has received strategic investments from some large biotech players whose names he can’t disclose, Schultz said the firm is looking to raise additional funding.
It wants to rapidly expand its staff of 12 employees and double its current 4,000-square-foot space, which houses both development and manufacturing. “We need that fuel for inventory and people to take our products to market,” Schultz said.
Life as the co-founder of a small startup company is a big change of pace for Lee, who spent his entire career in much larger firms – Amgen has 17,400 employees – after obtaining his Ph.D. But founding a company also puts Lee in charge of his own destiny in a way that’s not possible working for a blue chip ticker symbol.
“In any big company like Merck or Amgen, you always have a specific function. Here, I have to do everything from purchasing a desk to sometimes cleaning the bathrooms,” Lee said. Starting his own firm, he said, “ is the most exciting thing I’ve done in my career.”
• Contact Stephen Nellis at [email protected]